Cargando…

A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic

Detalles Bibliográficos
Autores principales:	Church, Matt, Taylor, Paul, Summers, Yvonne, Califano, Raffaele, Rafee, Shereen, Dixon, Mairead, Clarke, Lisa, Cove-Smith, Laura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. Published by Elsevier B.V. 2021
Materias:	Mesothelioma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159462/ http://dx.doi.org/10.1016/S0169-5002(21)00276-2

Ejemplares similares

Moral distress in mesothelioma and lung cancer nurses during the COVID-19 pandemic: insights from a UK survey
por: Hargreaves, Sarah, et al.
Publicado: (2023)

Systemic Treatments for Mesothelioma: Standard and Novel
por: Kindler, Hedy Lee
Publicado: (2008)

Successful treatment of a patient with oligometastatic mesothelioma to the brain
por: Li, Selena S., et al.
Publicado: (2020)

Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015)

Catching a shark while looking for flounders
por: Orlandi, Riccardo, et al.
Publicado: (2023)

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Extended pleurectomy and decortication: Video atlas of operative steps
por: Ripley, R. Taylor, et al.
Publicado: (2021)

Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma
por: Ohsawa, Manato, et al.
Publicado: (2023)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
por: Haakensen, Vilde Drageset, et al.
Publicado: (2021)

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
por: Fennell, Dean A, et al.
Publicado: (2021)

Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy
por: Obinata, Daisuke, et al.
Publicado: (2022)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2023)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
por: Wu, Wen-Chi, et al.
Publicado: (2022)

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2020)

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Management of Septated Malignant Pleural Effusions
por: Banka, Radhika, et al.
Publicado: (2018)

Chest Drain Size: the Debate Continues
por: Hallifax, Robert J., et al.
Publicado: (2017)

Thoracic Ultrasound: What Non-radiologists Need to Know
por: Williamson, Jonathan P., et al.
Publicado: (2017)

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
por: Lim, Sun Min, et al.
Publicado: (2020)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
por: Ahmadzada, Tamkin, et al.
Publicado: (2020)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population
por: Wallia, Amisha, et al.
Publicado: (2021)

Learning from the past to design better trials in second-line treatment for mesothelioma patients
por: Addeo, Alfredo, et al.
Publicado: (2018)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
por: Kim, Roger Y., et al.
Publicado: (2021)

The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma
por: Wheatley-Price, Paul, et al.
Publicado: (2022)

Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients
por: Holzknecht, Arnulf, et al.
Publicado: (2022)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers
por: Săftescu, Sorin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lb91hd68rr7cuasvpnfa9up82h